These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24161214)

  • 21. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions.
    Fioramonti M; Santini D; Iuliani M; Ribelli G; Manca P; Papapietro N; Spiezia F; Vincenzi B; Denaro V; Russo A; Tonini G; Pantano F
    Oncotarget; 2017 Mar; 8(12):20113-20121. PubMed ID: 28223547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts.
    Akune T; Ogata N; Hoshi K; Kubota N; Terauchi Y; Tobe K; Takagi H; Azuma Y; Kadowaki T; Nakamura K; Kawaguchi H
    J Cell Biol; 2002 Oct; 159(1):147-56. PubMed ID: 12379806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease.
    Stalvey MS; Clines KL; Havasi V; McKibbin CR; Dunn LK; Chung WJ; Clines GA
    PLoS One; 2013; 8(11):e80098. PubMed ID: 24236172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Novel, Direct NO Donor Regulates Osteoblast and Osteoclast Functions and Increases Bone Mass in Ovariectomized Mice.
    Kalyanaraman H; Ramdani G; Joshua J; Schall N; Boss GR; Cory E; Sah RL; Casteel DE; Pilz RB
    J Bone Miner Res; 2017 Jan; 32(1):46-59. PubMed ID: 27391172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss.
    Wang L; Liu S; Quarles LD; Spurney RF
    Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E826-34. PubMed ID: 15585587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abnormal bone architecture in mice expressing MyD88 in cells of the osteoclast lineage.
    Suren C; Lukashova L; Wischmann J; Wulsten D; Wildemann B; Von Eisenhart-Rothe R; Holzmann B; Mayer-Kuckuk P
    J Biol Regul Homeost Agents; 2019; 33(4):1105-1111. PubMed ID: 31332987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption.
    Xiong L; Jung JU; Wu H; Xia WF; Pan JX; Shen C; Mei L; Xiong WC
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3487-92. PubMed ID: 25733894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats.
    Mai QG; Zhang ZM; Xu S; Lu M; Zhou RP; Zhao L; Jia CH; Wen ZH; Jin DD; Bai XC
    J Cell Biochem; 2011 Oct; 112(10):2902-9. PubMed ID: 21618594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombin receptor deficiency leads to a high bone mass phenotype by decreasing the RANKL/OPG ratio.
    Tudpor K; van der Eerden BC; Jongwattanapisan P; Roelofs JJ; van Leeuwen JP; Bindels RJ; Hoenderop JG
    Bone; 2015 Mar; 72():14-22. PubMed ID: 25460576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Commensal Microbiota Enhance Both Osteoclast and Osteoblast Activities.
    Uchida Y; Irie K; Fukuhara D; Kataoka K; Hattori T; Ono M; Ekuni D; Kubota S; Morita M
    Molecules; 2018 Jun; 23(7):. PubMed ID: 29937485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ubiquitin ligase Cbl-b downregulates bone formation through suppression of IGF-I signaling in osteoblasts during denervation.
    Suzue N; Nikawa T; Onishi Y; Yamada C; Hirasaka K; Ogawa T; Furochi H; Kosaka H; Ishidoh K; Gu H; Takeda S; Ishimaru N; Hayashi Y; Yamamoto H; Kishi K; Yasui N
    J Bone Miner Res; 2006 May; 21(5):722-34. PubMed ID: 16734387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteocyte network; a negative regulatory system for bone mass augmented by the induction of Rankl in osteoblasts and Sost in osteocytes at unloading.
    Moriishi T; Fukuyama R; Ito M; Miyazaki T; Maeno T; Kawai Y; Komori H; Komori T
    PLoS One; 2012; 7(6):e40143. PubMed ID: 22768243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with N- and C-terminal peptides of parathyroid hormone-related protein partly compensate the skeletal abnormalities in IGF-I deficient mice.
    Rodríguez-de la Rosa L; López-Herradón A; Portal-Núñez S; Murillo-Cuesta S; Lozano D; Cediel R; Varela-Nieto I; Esbrit P
    PLoS One; 2014; 9(2):e87536. PubMed ID: 24503961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Parathyroid and bone. Effects of parathyroid hormone on bone resorption and formation: differences between intermittent and continuous treatment].
    Kaji H
    Clin Calcium; 2007 Dec; 17(12):1836-42. PubMed ID: 18057658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteoprotegerin deficiency attenuates strontium-mediated inhibition of osteoclastogenesis and bone resorption.
    Peng S; Liu XS; Zhou G; Li Z; Luk KD; Guo XE; Lu WW
    J Bone Miner Res; 2011 Jun; 26(6):1272-82. PubMed ID: 21611968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts.
    Nakamichi Y; Udagawa N; Kobayashi Y; Nakamura M; Yamamoto Y; Yamashita T; Mizoguchi T; Sato M; Mogi M; Penninger JM; Takahashi N
    J Immunol; 2007 Jan; 178(1):192-200. PubMed ID: 17182555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temporal and spatial expression of osteoprotegerin and receptor activator of nuclear factor -kappaB ligand during mandibular distraction in rats.
    Zhu WQ; Wang X; Wang XX; Wang ZY
    J Craniomaxillofac Surg; 2007 Mar; 35(2):103-11. PubMed ID: 17449257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An experimental model of partial insulin-like growth factor-1 deficiency in mice.
    Castilla-Cortazar I; Guerra L; Puche JE; Muñoz U; Barhoum R; Escudero E; Lavandera JL
    J Physiol Biochem; 2014 Mar; 70(1):129-39. PubMed ID: 24043429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
    Palmqvist P; Persson E; Conaway HH; Lerner UH
    J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levels of oxidative stress biomarkers and bone resorption regulators in apical periodontitis lesions infected by Epstein-Barr virus.
    Jakovljevic A; Andric M; Nikolic N; Coric V; Krezovic S; Carkic J; Knezevic A; Beljic-Ivanovic K; Pljesa-Ercegovac M; Miletic M; Soldatovic I; Radosavljevic T; Jovanovic T; Simic T; Ivanovic V; Milasin J
    Int Endod J; 2018 Jun; 51(6):593-604. PubMed ID: 29315650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.